Related Experiment Video
Updated: Jan 28, 2026

A High-content Assay for Monitoring AMPA Receptor Trafficking
Published on: January 28, 2019
An IQSEC2 Mutation Associated With Intellectual Disability and Autism Results in Decreased Surface AMPA Receptors
Eli J Rogers1, Reem Jada1, Kinneret Schragenheim-Rozales1
1Technion Faculty of Medicine, Technion Israel Institute of Technology, Haifa, Israel.
Abstract:
We have recently described an A350V mutation in IQSEC2 associated with intellectual disability, autism and epilepsy. We sought to understand the molecular pathophysiology of this mutation with the goal of developing targets for drug intervention. We demonstrate here that the A350V mutation results in interference with the binding of apocalmodulin to the IQ domain of IQSEC2. We further demonstrate that this mutation results in constitutive activation of the guanine nucleotide exchange factor (GEF) activity of IQSEC2 resulting in increased production of the active form of Arf6. In a CRISPR generated mouse model of the A350V IQSEC2 mutation, we demonstrate that the surface expression of GluA2 AMPA receptors in mouse hippocampal tissue was significantly reduced in A350V IQSEC2 mutant mice compared to wild type IQSEC2 mice and that there is a significant reduction in basal synaptic transmission in the hippocampus of A350V IQSEC2 mice compared to wild type IQSEC2 mice. Finally, the A350V IQSEC2 mice demonstrated increased activity, abnormal social behavior and learning as compared to wild type IQSEC2 mice. These findings suggest a model of how the A350V mutation in IQSEC2 may mediate disease with implications for targets for drug therapy. These studies provide a paradigm for a personalized approach to precision therapy for a disease that heretofore has no therapy.
Insights
A mutation in IQSEC2 causes intellectual disability, autism, and epilepsy by disrupting protein binding and activating a key signaling pathway. Mouse models show reduced synaptic function and behavioral deficits, suggesting new therapeutic targets.
Area of Science:
- Neuroscience
- Genetics
- Molecular Biology
Background:
- Intellectual disability, autism, and epilepsy are complex neurodevelopmental disorders.
- The IQSEC2 gene and its associated mutations are implicated in these conditions.
- Understanding the molecular basis of IQSEC2 mutations is crucial for developing effective therapies.
Purpose of the Study:
- To elucidate the molecular pathophysiology of the A350V mutation in IQSEC2.
- To identify potential drug targets for treating neurodevelopmental disorders caused by this mutation.
Main Methods:
- Investigated the effect of the A350V mutation on apocalmodulin binding to IQSEC2.
- Assessed the guanine nucleotide exchange factor (GEF) activity of mutated IQSEC2 and its impact on Arf6.
- Utilized a CRISPR-generated mouse model to study the mutation's effects on hippocampal GluA2 AMPA receptor surface expression and synaptic transmission.
- Evaluated behavioral phenotypes in mutant mice, including activity levels, social behavior, and learning.
Main Results:
- The A350V mutation impairs apocalmodulin binding to IQSEC2.
- This mutation leads to constitutive activation of IQSEC2's GEF activity, increasing active Arf6 production.
- Mutant mice exhibit reduced surface expression of GluA2 AMPA receptors and impaired basal synaptic transmission in the hippocampus.
- A350V IQSEC2 mutant mice display increased activity, abnormal social behavior, and learning deficits.
Conclusions:
- The A350V mutation in IQSEC2 disrupts protein interactions and signaling pathways, leading to neurophysiological and behavioral abnormalities.
- These findings provide a mechanistic model for IQSEC2-related neurodevelopmental disorders.
- The study highlights potential therapeutic targets for a personalized, precision medicine approach to these conditions.
Related Concept Videos
Intellectual Disability
Types of Receptors: Cell Surface Receptors
Mutations
Decreasing Function
Learning Disabilities
Dyslexia
Dyslexia is a...
Viral Mutations

